Glenmark pharmaceuticals ltd - Latest News Update, Information, Photos & Videos on Glenmark pharmaceuticals ltd at Lokmat Times

Glenmark Pharmaceuticals will introduce a 400 mg version of oral anti-viral FabiFlu for the treatment of mild to moderate Covid-19 in India.The higher strength will improve patient compliance and experience by effectively reducing the number of tablets that patients require per day, the pharma major said on Thursday.A higher pill burden has been associated with lower adherence to therapy, the latter affecting viral suppression and overall treatment outcomes. Reducing the pill burden has been a demand from doctors and patients to enable adherence."Introducing this higher strength of FabiFlu is in line with these efforts to ensure a smoother experience for patients by reducing their daily pill burden," said Monika Tandon, Vice President and Head of Clinical Development, Global Specialty and Branded Portfolio.Glenmark said it has also commenced a post-marketing surveillance study on FabiFlu to closely monitor the efficacy and safety of the drug in a large pool of patients prescribed with the oral antiviral Favipiravir as part of an open-label, multi-centre, single-arm study.The company is also conducting another phase three clinical trial to evaluate the efficacy of two anti-virals drugs Favipiravir and Umifenovir as a combination therapy in moderate hospitalised adult Covid-19 patients in India.( With inputs from ANI )

Glenmark Pharmaceuticals LtdFOLLOW

Glenmark pharmaceuticals ltd, Latest News

Glenmark Life Sciences Ltd, a wholly-owned subsidiary of Glenmark Pharmaceuticals Ltd, has filed a draft red herring prospectus with the Securities and Exchange Board of India for an initial public offer (IPO) to raise Rs 1,160 crore. ...

Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today announced that its subsidiary Glenmark Specialty S.A. in Switzerland and an affiliate of Bausch Health Companies Inc. have entered into an exclusive licensing a ...

Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today received the "India Pharma Innovation of the Year" award, as part of the India Pharma & India Medical Device Awards 2021. ...

Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today launched SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India. ...

Highlights for Q1 FY 2020-21 ...

New Delhi, Aug 6 Glenmark Pharmaceuticals, a research-led global pharmaceutical company, on Thursday announced that it is set to ... ...

Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, today announced that it will introduce a 400 mg version of oral antiviral FabiFlu®, for the treatment of mild to moderate COVID-19 in India. ...

Glenmark Pharmaceuticals will introduce a 400 mg version of oral anti-viral FabiFlu for the treatment of mild to moderate Covid-19 in India. ...